Oxidative stress in lymphoma: similarities and differences between dog and human
Abstract In the last 20 years, an increasing interest toward oxidative stress has been documented in order to investigate their direct or indirect involvement in several mechanisms regarding oncogenesis and lymphomas in particular. The aim of this paper was to evaluate oxidative stress in dogs affected by malignant lymphoma in comparison to a control group, to investigate what factors can affect this status, and to point out similarities and differences with human. Forty-eight samples from four subjects, affected by high-grade centroblastic polymorphic lymphoma and receiving a standard chemotherapy, have been processed for derivatives of reactive oxygen metabolites (d-ROMs) and biological antioxidant potential (BAP) tests. The obtained data show a condition of oxidative stress in dogs with lymphoma, with a significant increase in reactive oxygen species (ROS) plasma levels and a decrease in antioxidant capacity. No significant differences emerged on the basis of remission. Further results of canine studies about oxidative status in lymphomas could be a model for human, according to analogy between them.
ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is standard upfront chemotherapy for adults diagnosed with Hodgkin lymphoma (HL), but positron emission tomography (PET)-based response data following ABVD is lacking for pediatrics. Among children who received ABVD for HL, we document interim and end of therapy PET-computed tomography (CT) response by Deauville criteria, and survival outcomes following a response-based reduction in involved field radiotherapy (IFRT). Children 18 years of age or below with HL treated with ABVD between 2006 and 2015 who had interim PET/CT scans after 2 cycles of chemotherapy were inclu...
In conclusion, treatment with blinatumomab is effective and tolerable in adult patients with relapsed/refractory B-ALL outside of a clinical trial stetting.
Conclusion 18F-FDG PET/CT seemed to be an excellent diagnostic test in assessment of BMI at initial assessment and staging of Hodgkin lymphoma and DLBCL patients.
Authors: Al-Juhaishi T, Mckay J, Sindel A, Yazbeck V Abstract Introduction: Double-hit (DHL) and triple-hit lymphomas (THL) have long been among the most clinically aggressive molecular subtypes of diffuse large B-cell lymphomas. In the 2016 revised WHO classification, they represent a new entity called high-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6. Unlike most B-cell lymphomas, they have poor response to standard R-CHOP therapy, tend to quickly develop resistance to cytotoxic chemotherapies, and are associated with higher central nervous system (CNS) infiltration. This can lead to incr...
We retrospectively analyzed 48 CNS lymphoma patients who received HDC/ASCT using TBC conditioning. We found a 2-year PFS and OS rate of 80.5% and 80.1%, respectively. Toxicities included nausea/vomiting, diarrhea, mucositis, and febrile neutropenia. Treatment-related mortality was 8.3% in the first 100 days post-transplant. This data supports the use of consolidative ASCT in PCNSL and secondary CNS lymphoma patients.
In conclusion, concordant BM infiltration represents a subset with poor prognosis, whereas the prognostic impact of discordant BM infiltration could be limited to non-CGB cases.
CONCLUSION: miR-21 and miR-155 promote the progression of Burkitt's lymphoma through PI3K/AKT signaling by targeting C1RL and TCAP. Our findings will provide a novel biomarker and therapeutic strategies for Burkitt's lymphoma. PMID: 32055277 [PubMed]
CONCLUSIONS: This is the first report on discordant lymphoma consisting of mantle cell lymphoma and angioimmunoblastic T cell lymphoma. There seems to be no relation these two different kinds of lymphoma, and EBV infection might prompt the development of angioimmunoblastic T cell lymphoma after transplantation. Rash is a common clinical manifestation when T cell lymphoma develops after treatment for MCL. PMID: 32055275 [PubMed]
Publication date: Available online 15 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Alan Burnett, Richard StoneAbstractDespite the approval of 8 new drugs for AML since 2017, the disease remains challenging given the significant toxicity associated with available treatments and relatively low cure rates, especially in older adults. While advantageous for patients, self-congratulatory rejoicing about the new agents would be extremely premature. Questions abound about the need for a specific vs less specific FLT3 inhibitor (e.g midostautin) in the upfront setting and whether a single agent (gilteritni...
Conclusions: In Polish lymphoma patients the incidence of positive HBsAg and/or anti-HBc results is consistent with the prevalence in the United States or Australia. The adherence to appropriate HBV screening guidelines in Polish centers is not sufficient. We should intensify educational strategies in the global oncohematologic medical community. PMID: 32051719 [PubMed]